This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis

This study has been completed.
Information provided by:
University Hospital Tuebingen Identifier:
First received: January 9, 2008
Last updated: June 9, 2008
Last verified: June 2008
The purpose of this study is to compare adhesion prophylaxis with polylactide-caprolactone-trimethylenecarbonate copolymer to icodextrin 4% in terms of safety, side effects and usability in addition to gaining early evidence of the effectiveness of polylactide-caprolactone-trimethylenecarbonate copolymer.

Condition Intervention Phase
Adhesions Device: polylactide-caprolactone-trimethylenecarbonate copolymer Device: Icodextrin 4% Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Prevention
Official Title: Safety Study of Polylactide-Caprolactone-Trimethylenecarbonate Copolymer for Post-Operative Adhesion Prophylaxis

Resource links provided by NLM:

Further study details as provided by University Hospital Tuebingen:

Primary Outcome Measures:
  • Difference in visual analogue pain score on visit 8 after discharge minus visit 1 on admission [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Use of analgesia [ Time Frame: 1, 2 and 3 days ]
  • Post-operative pyrexia [ Time Frame: 3 months ]
  • Post-operative infection [ Time Frame: 3 months ]
  • Requirement for re-operation [ Time Frame: 3 months ]
  • Dysmenorrhoea [ Time Frame: 3 months ]
  • Dyspareunia [ Time Frame: 3 months ]
  • Constipation [ Time Frame: 3 months ]
  • Diarrhoea [ Time Frame: 3 months ]
  • Nausea [ Time Frame: 3 months ]
  • Duration of adhesion prophylaxis [ Time Frame: Day 1 ]
  • Usability as assessed by surgeon [ Time Frame: Day 1 ]

Estimated Enrollment: 30
Study Start Date: January 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Device: polylactide-caprolactone-trimethylenecarbonate copolymer
Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
Active Comparator: 2 Device: Icodextrin 4%
1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18-60 years
  • sex female
  • laparoscopic myomectomy indicated
  • ability and intention to conform to the study protocol
  • written informed consent

Exclusion Criteria:

  • pregnancy
  • indication for laparotomy
  • inflammatory bowel disease
  • additional surgical interventions
  • known or suspected intollerance or hypersensibility to the interventions
  • chronic pain
  • systemic corticoids or irradiation
  • alcohol abuse or other substance abuse
  • clinical signs of malignancy
  • psychiatric or neurological disease
  • participation in another clinical trial within 30 days
  • inability to understand the purpose of the trial or to conform to the study protocol
  • absence of written informed consent
  • inflammation of pelvic organs
  • presence of adhesions which lead to a conversion from laparoscopy to laparotomy
  • concurrent therapy with corticoids, anti-neoplastic agents or irradiation
  • maintenance therapy with non-steroidal anti-inflammatory drugs or analgesics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00597662

Universitäts-Frauenklinik Tübingen
Tübingen, Baden-Wuerttemberg, Germany, 72076
Sponsors and Collaborators
University Hospital Tuebingen
Study Chair: Diethelm Wallwiener, Prof. Dr. Universitäts-Frauenklinik Tübingen
  More Information

Responsible Party: Prof. Dr. D. Wallwiener, Universitäts-Frauenklinik Tübingen Identifier: NCT00597662     History of Changes
Other Study ID Numbers: SUP-002
Study First Received: January 9, 2008
Last Updated: June 9, 2008

Additional relevant MeSH terms:
Tissue Adhesions
Pathologic Processes
Dialysis Solutions
Pharmaceutical Solutions processed this record on June 23, 2017